Research programme: human embryonic stem cell based therapeutics - ImStem Biotechnology

Drug Profile

Research programme: human embryonic stem cell based therapeutics - ImStem Biotechnology

Alternative Names: IMS 001/IMS 002; IMSB 001; IMSO 001; IMSP 001

Latest Information Update: 18 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImStem Biotechnology
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Arthritis; Bone disorders; Burns; Corneal disorders; Diabetic foot ulcer; Inflammatory bowel diseases; Multiple sclerosis; Sjogren's syndrome; Spinal cord injuries

Most Recent Events

  • 16 Jun 2014 Preclinical trials in Arthritis in USA (unspecified route)
  • 16 Jun 2014 Preclinical trials in Bone disorders (bone repair) in USA (unspecified route)
  • 16 Jun 2014 Preclinical trials in Burns in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top